(1) durable resonse rate for cavatak is 19.3% vs 16% for T-vec
(2) 1 year survival is 75.4% for Cavatak vs 58% for T-vec
(3) disease had not progressed in more than half of all responders at 16.5 months
(4) more than half of all patients were alive after 16.5 months
(5) Far superior safety profile: NO grade 3 or 4 AEs (adverse events) vs 37% of patients in T-vec phase III experienced a grade 3 or 4 AE. T-vec also poses a potential threat to healthcare works, whereas cavatak poses none.
VLA Price at posting:
45.0¢ Sentiment: Buy Disclosure: Held
